Quick Answer
ACRO BIOMEDICAL CO., LTD. reported Operating Income Loss of -$154.0 thousand for the year ending 2025.
- ACRO BIOMEDICAL CO., LTD. showed a decrease of -305.8% in Operating Income Loss from 2024 to 2025.
- This data is from ACRO BIOMEDICAL CO., LTD.'s annual report (Form 10-K), filed with the SEC on February 11, 2026.
- XBRL data for this metric is available from 2017 to 2025 (10 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 10 years of available data (2017 to 2025), ACRO BIOMEDICAL CO., LTD.'s Operating Income Loss has declined by 6,751.6%.
- Historical annual values: Fiscal year 2025: -$154.0 thousand | Fiscal year 2024: -$38.0 thousand | Fiscal year 2023: -$8.80 million | Fiscal year 2022: -$15.87 million | Fiscal year 2021: -$7.69 million | Fiscal year 2020: -$130.5 thousand | Fiscal year 2019: -$422.8 thousand | Fiscal year 2019: -$441.6 thousand | Fiscal year 2018: $515.6 thousand | Fiscal year 2017: -$2.2 thousand.
- Data sourced from SEC EDGAR public filings as of June 23, 2026.
Last verified: